Figures computed from official regulatory filings — .
Analysttarget 7 USD (+1792%) · consensus 3/5 · 0 buy · 2 hold · 0 sell
Ownershipinsiders 0.98% · institutions 70.98% · short 29.1% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for HERON THERAPEUTICS, INC. /DE/ only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. Heron Therapeutics, Inc. was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. The company was founded in 1983 and is headquartered in Cary, North Carolina.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
52 buys86 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Hensley Mark Earl | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Hensley Mark Earl | Other | $4.4K | SEC |
| Hensley Mark Earl | Exercise | n/a (No price was disclosed in the filing) | SEC |
| Duarte Ira | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Forbes William Ptrack record | Other | $1.7K | SEC |
| Forbes William Ptrack record | Exercise | n/a (No price was disclosed in the filing) | SEC |
| Collard Craig Atrack record | Exercise | n/a (No price was disclosed in the filing) | SEC |
| Collard Craig Atrack record | Exercise | n/a (No price was disclosed in the filing) | SEC |
| Duarte Ira | Exercise | n/a (No price was disclosed in the filing) | SEC |
| Forbes William Ptrack record | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Hensley Mark Earl | Exercise | n/a (No price was disclosed in the filing) | SEC |
| Collard Craig Atrack record | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Forbes William Ptrack record | Exercise | n/a (No price was disclosed in the filing) | SEC |
| Forbes William Ptrack record | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Duarte Ira | Other | $1.7K | SEC |
| Collard Craig Atrack record | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Hensley Mark Earl | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Duarte Ira | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Duarte Ira | Other | $1.9K | SEC |
| Duarte Ira | Exercise | n/a (No price was disclosed in the filing) | SEC |
| Forbes William Ptrack record | Other | $1.7K | SEC |
| Duarte Ira | Other | $517.5 | SEC |
| Duarte Ira | Exercise | n/a (No price was disclosed in the filing) | SEC |
| Forbes William Ptrack record | Other | $517.5 | SEC |
| Collard Craig Atrack record | Exercise | n/a (No price was disclosed in the filing) | SEC |